Companies › ThromBio
1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TBO-309 PI3Kβ inhibitor that blocks platelet activation, adhesion, and aggregation | PIK3CB | Phase 2 | Ischemic Stroke; Acute Ischemic Stroke | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05363397 | TBO-309 | Phase 2 | Acute Ischemic Stroke | Neurology | Feb 2026 |
| NCT06813651 | TBO-309 | Phase 2 | Ischemic Stroke | Neurology | Dec 2026 |
Dasher Neuroscience Appello Pharmaceuticals PhenoNet Glycomine RyCarma Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.